The International Alliance for Biological Standardization and the Coalition for Epidemic Preparedness Innovations organized a joint webinar on the use of platform technologies for vaccine development. To tackle new emerging infectious diseases, including SARS-CoV-2, rapid response platforms, using the same basic components as a backbone, yet adaptable for use against different pathogens by inserting new genetic or protein sequences, are essential. Furthermore, it is evident that development of platform technologies needs to continue, due to the emerging variants of SARS-CoV-2. The objective of the meeting was to discuss techniques for platform manufacturing that have been used for COVID-19 vaccine development, with input from regulatory authorities on their experiences with, and expectations of, the platforms.

Industry and regulators have been very successful in cooperating, having completed the whole process from development to licensing at an unprecedented speed. However, we should learn from the experiences, to be able to be even faster when a next pandemic of disease X occurs.

国际生物标准化联盟和流行病防范创新联盟组织了一次关于使用平台技术进行疫苗开发的联合网络研讨会。为了应对包括 SARS-CoV-2 在内的新出现的传染病，使用相同的基本组件作为主干，但通过插入新的遗传或蛋白质序列来适应不同病原体的快速反应平台是必不可少的。此外，很明显，由于 SARS-CoV-2 的新变种，平台技术的开发需要继续进行。会议的目的是讨论已用于 COVID-19 疫苗开发的平台制造技术，并听取监管机构对平台的经验和期望的意见。

行业和监管部门的合作非常成功，以前所未有的速度完成了从开发到许可的全过程。但是，我们应该从经验中吸取教训，以便在下一次 X 疾病大流行发生时能够更快。